Solid Biosciences (SLDB) Accumulated Expenses (2017 - 2026)

Solid Biosciences has reported Accumulated Expenses for 10 years, with the latest figure at $19.2 million in Q1 2026.

• Quarterly Accumulated Expenses rose 31.6% year-over-year to $19.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.2 million (up 31.6% YoY) and the FY2025 annual result came in at $18.9 million, down 4.57% from the prior year.
• Accumulated Expenses improved to $19.2 million in Q1 2026 per SLDB's latest filing, from $18.9 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $19.9 million in Q4 2024 and troughed at $9.4 million in Q1 2022.
• A 5-year average of $14.0 million and a median of $13.2 million in 2024 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2023: Accumulated Expenses jumped 109.24% in 2022, then sank 39.12% in 2023.
• Over 5 years, Accumulated Expenses stood at $16.7 million in 2022, then tumbled by 39.12% to $10.2 million in 2023, then soared by 95.37% to $19.9 million in 2024, then declined by 4.57% to $18.9 million in 2025, then climbed by 1.25% to $19.2 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $19.2 million, $18.9 million, and $19.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.